GO:0015173 aromatic amino acid transmembrane transporter activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0015173 describes the molecular function that enables transfer of aromatic amino acids (tryptophan, tyrosine, phenylalanine, and related ring-containing amino acids) across biological membranes.
• Aromatic amino acid transporters are members of the SLC superfamily, including SLC7A5 (LAT1), SLC16A10 (MCT10), and SLC43A2 (LAT4), which mediate sodium-independent or sodium-dependent transport.
• Substrate recognition relies on aromatic side chains and specific residues within the transporter's substrate-binding pocket, as shown for LAT1 and MCT10.
• Dysregulated aromatic amino acid transport is linked to cancer (e.g., LAT1 overexpression in tumors), neurological disorders, and metabolic diseases.
• CRISPR-based knockout, point mutation, and knock-in models are essential to dissect the physiological roles of these transporters and validate them as drug targets.
• EDITGENE provides custom cell models and CRISPR library screening to accelerate research on aromatic amino acid transporters and their disease relevance.
Description
Aromatic amino acid transmembrane transporter activity (GO:0015173) is a molecular function that enables the movement of aromatic amino acids, such as tryptophan, tyrosine, and phenylalanine, across cell membranes. These amino acids are not only building blocks for protein synthesis but also precursors for neurotransmitters, hormones, and signaling molecules, making their transport critical for cellular metabolism and communication. The transporters mediating this activity belong to the solute carrier (SLC) family, including SLC7A5 (LAT1), SLC16A10 (MCT10), and SLC43A2 (LAT4), which are expressed in various tissues and play key roles in nutrient uptake and drug disposition. Research on aromatic amino acid transporters has gained momentum due to their involvement in cancer, where they supply tumor cells with essential amino acids, and in neurological disorders, where altered transport affects neurotransmitter homeostasis. Structural and functional studies have revealed how these transporters recognize aromatic substrates and how mutations can alter their specificity. Understanding GO:0015173 is therefore fundamental for developing targeted therapies and for interpreting metabolic phenotypes in disease models. This article synthesizes current knowledge from authoritative QuickGO annotations and verified PubMed literature to provide a comprehensive overview of the mechanism, genes, and research methods associated with aromatic amino acid transmembrane transporter activity.
aromatic amino acid transmembrane transporter activity At A Glance
| GO ID | GO:0015173 |
|---|---|
| GO term | aromatic amino acid transmembrane transporter activity |
| Ontology | molecular_function |
| Synonym | aromatic amino acid transporter activity; hydroxy/aromatic amino acid permease activity; valine/tyrosine/tryptophan permease activity |
| Major function | Enables the transfer of aromatic amino acids across membranes |
| Substrates | Tryptophan, tyrosine, phenylalanine, and related aromatic amino acids |
| Representative genes | SLC7A5 (LAT1), SLC16A10 (MCT10), SLC43A2 (LAT4), SLC3A2 (4F2hc) |
| Cellular location | Plasma membrane, sometimes intracellular membranes |
| Disease relevance | Cancer, neurological disorders, metabolic diseases |
What Is GO:0015173?
Aromatic amino acid transmembrane transporter activity (GO:0015173) is defined as the transfer of aromatic amino acids from one side of a membrane to the other. Aromatic amino acids are characterized by an aromatic ring in their side chain, such as tryptophan, tyrosine, and phenylalanine. This activity is mediated by integral membrane proteins that facilitate the passage of these amino acids across cellular membranes, often in a sodium-dependent or sodium-independent manner.
Why Is aromatic amino acid transmembrane transporter activity Important in Cell Biology?
Aromatic amino acid transporters are essential for maintaining intracellular amino acid pools, supporting protein synthesis, and regulating neurotransmitter precursor availability. Their dysfunction contributes to a range of pathologies, including cancer, where LAT1 is overexpressed to fuel tumor growth, and neurological disorders linked to impaired tryptophan and tyrosine transport. Moreover, these transporters influence drug pharmacokinetics, as they can mediate the uptake of therapeutic agents such as L-DOPA and thyroid hormones. Thus, understanding GO:0015173 is critical for both basic biology and translational research.
• Supplies essential aromatic amino acids for protein synthesis and cell growth.
• Regulates neurotransmitter precursors (tryptophan, tyrosine) in the brain.
• Overexpressed in many cancers, supporting metabolic reprogramming.
• Mediates transport of drugs and hormones, affecting pharmacokinetics.
• Mutations in transporters can cause metabolic disorders and neurological diseases.
• Provides targets for cancer therapy and drug delivery.
• Involved in immune cell function and inflammation.
• Key to understanding amino acid homeostasis in development and aging.
• Enables cross-talk between metabolism and signaling pathways.
• Offers opportunities for CRISPR-based functional genomics.
What Happens During aromatic amino acid transmembrane transporter activity?
Substrate recognition and binding
In simple terms: The transporter first grabs the aromatic amino acid from one side of the membrane.
Aromatic amino acid transporters possess a substrate-binding site that selectively recognizes aromatic side chains. For example, LAT1 (SLC7A5) forms a heterodimer with 4F2hc (SLC3A2) and uses a hydrophobic pocket to accommodate large aromatic residues, as revealed by structural studies. Similarly, MCT10 (SLC16A10) can transport aromatic amino acids, and few amino acid exchanges can expand its substrate spectrum. The binding affinity and specificity are determined by residues within the transmembrane domains.
Conformational change and translocation
In simple terms: The transporter changes shape to move the amino acid across the membrane.
Upon substrate binding, the transporter undergoes conformational changes that expose the substrate to the opposite side of the membrane. This alternating access mechanism is common to SLC transporters. For LAT1, structural analyses have captured distinct inward- and outward-facing states, highlighting the dynamics of the transport cycle. The process can be sodium-dependent or sodium-independent, depending on the transporter family.
Substrate release and resetting
In simple terms: The amino acid is released inside the cell, and the transporter resets for another round.
After translocation, the aromatic amino acid is released into the cytoplasm, and the transporter returns to its initial conformation. This step is crucial for maintaining directional transport and is regulated by intracellular substrate concentrations and interacting proteins. For example, MCT10-mediated transport is influenced by intracellular pH and substrate gradients.
Regulation by associated proteins
In simple terms: Other proteins can help or hinder the transporter's activity.
Many aromatic amino acid transporters require accessory proteins for proper trafficking and function. LAT1 needs 4F2hc (SLC3A2) for surface expression and stability. Similarly, other SLC transporters interact with chaperones or scaffolding proteins that modulate their activity. These interactions are potential targets for therapeutic intervention.
Key Genes Involved in GO:0015173 aromatic amino acid transmembrane transporter activity
The following genes encode transporters and associated proteins that mediate aromatic amino acid transmembrane transporter activity (GO:0015173).
| Gene | Major Role | Research Relevance |
|---|---|---|
| SLC7A5 (LAT1) | Sodium-independent transporter for large neutral amino acids including aromatic amino acids; forms heterodimer with SLC3A2 | Overexpressed in cancer; target for drug delivery and cancer therapy |
| SLC3A2 (4F2hc) | Accessory subunit for LAT1 and other SLC7 transporters; essential for surface expression | Required for LAT1 function; knockout affects amino acid transport |
| SLC16A10 (MCT10) | Sodium-independent transporter for aromatic amino acids and thyroid hormones | Substrate specificity can be altered by few mutations; involved in hormone transport |
| SLC43A2 (LAT4) | Sodium-independent transporter for large neutral amino acids including aromatic amino acids | Expressed in kidney and intestine; role in amino acid absorption |
| SLC7A8 (LAT2) | Sodium-independent transporter for small and large neutral amino acids | Broad substrate specificity; involved in amino acid homeostasis |
| SLC6A19 (B0AT1) | Sodium-dependent transporter for neutral amino acids including aromatic amino acids | Mutations cause Hartnup disorder; important for renal and intestinal transport |
| SLC36A1 (PAT1) | Proton-coupled transporter for small amino acids and some aromatic amino acids | Role in lysosomal amino acid sensing and mTORC1 signaling |
| SLC38A2 (SNAT2) | Sodium-dependent transporter for small neutral amino acids | Can transport some aromatic amino acids; involved in cell growth |
| SLC1A5 (ASCT2) | Sodium-dependent transporter for neutral amino acids | Major glutamine transporter; can also transport aromatic amino acids |
| SLC7A11 (xCT) | Cystine/glutamate antiporter; not primarily aromatic but can influence amino acid pools | Involved in redox balance and cancer |
| SLC25A22 (GC1) | Mitochondrial glutamate transporter; indirectly affects aromatic amino acid metabolism | Mutations cause epilepsy; role in mitochondrial transport |
| SLC16A1 (MCT1) | Monocarboxylate transporter; can transport aromatic amino acids under certain conditions | Broad substrate specificity; involved in cancer metabolism |
| SLC16A7 (MCT2) | Monocarboxylate transporter; high affinity for pyruvate and some amino acids | Expressed in neurons; role in energy metabolism |
| SLC7A1 (CAT-1) | Cationic amino acid transporter; not aromatic but related family | Model for studying SLC7 family mechanisms |
| SLC7A2 (CAT-2) | Cationic amino acid transporter; can transport some aromatic amino acids | Inducible in inflammation; role in immune response |
| SLC7A3 (CAT-3) | Cationic amino acid transporter; primarily arginine | Expressed in brain; potential role in neurotransmitter precursor transport |
| SLC7A4 (CAT-4) | Orphan transporter; related to CAT family | Less characterized; potential aromatic amino acid transport |
| SLC7A5 (LAT1) variants | Mutations can alter substrate specificity and transport activity | Studied using site-directed mutagenesis and CRISPR knock-in |
How Is aromatic amino acid transmembrane transporter activity Regulated?
Aromatic amino acid transporter activity is regulated at multiple levels. Transcriptionally, LAT1 (SLC7A5) is induced by oncogenic signaling pathways such as MYC and HIF-1α, linking transport to cell growth and hypoxia. Post-translationally, the interaction with 4F2hc (SLC3A2) is required for LAT1 stability and surface localization. Additionally, mTORC1 signaling senses intracellular amino acid levels and can feedback on transporter expression. For MCT10, substrate availability and pH influence transport rate. These regulatory mechanisms ensure that aromatic amino acid supply matches cellular demand.
aromatic amino acid transmembrane transporter activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SLC7A5 (LAT1) | Cancer; overexpression promotes tumor growth | Knockout and overexpression in cancer cell lines; xenograft models |
| SLC16A10 (MCT10) | Thyroid hormone transport; potential role in metabolic disorders | Point mutations to alter substrate specificity; knockout in thyroid cells |
| SLC6A19 (B0AT1) | Hartnup disorder; impaired neutral amino acid transport | Knockout mouse models; patient-derived cells |
| SLC3A2 (4F2hc) | Cancer; essential for LAT1 function | Knockout in cancer cells to disrupt LAT1 surface expression |
| SLC43A2 (LAT4) | Amino acid absorption; potential metabolic disorders | Knockout in kidney and intestine cell lines |
Cancer
Aromatic amino acid transporters, particularly LAT1 (SLC7A5), are overexpressed in many cancers to support the increased demand for amino acids required for proliferation. LAT1 transports large neutral amino acids, including tryptophan and tyrosine, which are precursors for biomass and signaling molecules. Its overexpression correlates with poor prognosis in various tumors, and inhibitors are being developed as anticancer agents. MCT10 (SLC16A10) has also been implicated in cancer metabolism, though its role is less defined.
Neurological disorders
In the brain, aromatic amino acid transporters regulate the availability of tryptophan and tyrosine, precursors for serotonin and dopamine, respectively. Dysfunction of these transporters has been linked to mood disorders, schizophrenia, and neurodegenerative diseases. For example, altered LAT1 function may affect neurotransmitter synthesis and contribute to depression. Additionally, mutations in SLC6A19 cause Hartnup disorder, characterized by impaired neutral amino acid transport including aromatic amino acids, leading to neurological symptoms.
Metabolic and endocrine disorders
MCT10 (SLC16A10) transports thyroid hormones and aromatic amino acids, and its dysfunction may affect thyroid hormone homeostasis. Furthermore, transporters like SLC43A2 (LAT4) are involved in renal and intestinal amino acid absorption; defects could lead to aminoacidurias. Understanding these roles is important for diagnosing and treating metabolic diseases.
From aromatic amino acid transmembrane transporter activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of SLC7A5 (LAT1) reduce tumor growth? | CRISPR knockout in cancer cell lines and mouse xenografts |
| How do point mutations in SLC16A10 alter substrate specificity? | CRISPR point mutation knock-in in cell lines, followed by transport assays |
| Can a tagged version of SLC3A2 reveal its interaction with LAT1? | Knock-in of epitope tag (e.g., HA or GFP) using CRISPR |
| What is the effect of SLC6A19 overexpression on amino acid transport? | CRISPR overexpression (e.g., CRISPRa) in renal epithelial cells |
| Which genes are essential for aromatic amino acid transport in cancer? | Genome-wide CRISPR knockout library screening |
| How does SLC43A2 contribute to amino acid homeostasis in vivo? | Conditional knockout mouse models |
How to Study the aromatic amino acid transmembrane transporter activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radiolabeled uptake assay | Transport activity of aromatic amino acids | Characterizing substrate specificity and kinetics |
| Cryo-EM | Three-dimensional structure of transporter | Understanding substrate binding and conformational changes |
| CRISPR knockout screen | Genes required for transport or cell fitness | Identifying novel regulators of aromatic amino acid transport |
| Co-immunoprecipitation | Protein-protein interactions | Detecting accessory subunits like 4F2hc |
| RNA-seq | Gene expression changes upon transporter perturbation | Assessing transcriptional responses to transport inhibition |
| Proximity labeling (BioID) | Interactome of transporter in living cells | Mapping dynamic interactions |
| Site-directed mutagenesis | Effect of specific residues on transport | Validating structural predictions |
| Metabolomics | Intracellular amino acid levels | Measuring impact of transporter activity on metabolism |
Transport assays
Radiolabeled or fluorescent aromatic amino acid uptake assays are used to measure transporter activity directly. Cells expressing the transporter of interest are incubated with substrates, and uptake is quantified over time. These assays can be performed in the presence or absence of sodium to distinguish transport modes.
Structural biology
Cryo-electron microscopy and X-ray crystallography have provided insights into the structure of LAT1 and other SLC transporters, revealing substrate-binding pockets and conformational states. These methods are essential for understanding how mutations affect function.
CRISPR screening
Genome-wide CRISPR knockout or activation screens can identify genes that regulate aromatic amino acid transport or that are synthetically lethal with transporter loss. Such screens are powerful for discovering new components of the transport pathway.
Proteomics and interactomics
Mass spectrometry-based proteomics can identify interacting partners of aromatic amino acid transporters, such as 4F2hc for LAT1. Proximity labeling techniques like BioID can map the transporter interactome in living cells.
How CRISPR Can Be Used to Study GO:0015173 aromatic amino acid transmembrane transporter activity
Knockout
CRISPR knockout of genes encoding aromatic amino acid transporters, such as SLC7A5 or SLC16A10, can abolish transport activity and reveal their physiological roles. Knockout cell lines are valuable for studying compensatory mechanisms and for drug sensitivity testing.
Point Mutation
Introducing specific point mutations into transporter genes via CRISPR can mimic naturally occurring variants or alter substrate specificity. For example, mutations in MCT10 can expand its substrate spectrum, as shown by Johannes et al.. Such models help dissect structure-function relationships.
Knock-in
Knock-in of tags (e.g., GFP, HA) or reporter genes allows visualization and tracking of transporters in live cells. This approach is useful for studying trafficking and localization of LAT1 and its partners. Knock-in of disease-associated mutations can create isogenic models for drug testing.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression can increase transporter levels to study gain-of-function effects, such as enhanced amino acid uptake and proliferation. Overexpression models are particularly relevant for cancer research, where LAT1 is often upregulated.
How EDITGENE Supports aromatic amino acid transmembrane transporter activity Research
Researchers studying aromatic amino acid transmembrane transporter activity-related genes often need to determine whether a candidate gene is causally involved in transport, disease, or drug response. EDITGENE provides a comprehensive suite of CRISPR-based services to create precise cellular models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for aromatic amino acid transmembrane transporter activity research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| SLC6A14 Knockout HEK293 Cell Line | EDJ-KQ7352 | Human | 11254 | Details Get a Quote |
| SLC16A10 Knockout HEK293 Cell Line | EDJ-KQ7604 | Human | 117247 | Details Get a Quote |
| SLC3A2 Knockout HEK293 Cell Line | EDJ-KQ17768 | Human | 6520 | Details Get a Quote |
| SLC7A5 Knockout HEK293 Cell Line | EDJ-KQ17900 | Human | 8140 | Details Get a Quote |
| SLC7A5 Knockout HeLa Cell Line | EDC08354 | Human | 8140 | Details Get a Quote |
| SLC16A10 Knockout A-549 Cell Line | EDJ-KQ32943 | Human | 117247 | Details Get a Quote |
| SLC3A2 Knockout A-549 Cell Line | EDC08247 | Human | 6520 | Details Get a Quote |
| SLC3A2 Knockout HCT 116 Cell Line | EDJ-KQ19842 | Human | 6520 | Details Get a Quote |
| SLC3A2 Knockout HeLa Cell Line | EDJ-KQ19843 | Human | 6520 | Details Get a Quote |
| SLC7A5 Knockout HCT 116 Cell Line | EDJ-KQ23377 | Human | 8140 | Details Get a Quote |
| SLC7A5 Knockout A-549 Cell Line | EDJ-KQ24766 | Human | 8140 | Details Get a Quote |
| SLC16A10 Knockout HCT 116 Cell Line | EDJ-KQ31597 | Human | 117247 | Details Get a Quote |
| SLC6A14 Knockout HeLa Cell Line | EDJ-KQ55613 | Human | 11254 | Details Get a Quote |
| SLC16A10 Knockout HeLa Cell Line | EDJ-KQ58012 | Human | 117247 | Details Get a Quote |
| SLC6A14 Knockout A-549 Cell Line | EDJ-KQ64112 | Human | 11254 | Details Get a Quote |
Displaying Records 1 To 15 Of 16 Records
Frequently Asked Questions About aromatic amino acid transmembrane transporter activity
What is aromatic amino acid transmembrane transporter activity?
It is a molecular function (GO:0015173) that enables the transfer of aromatic amino acids, such as tryptophan, tyrosine, and phenylalanine, across cell membranes.
What genes are involved in aromatic amino acid transmembrane transporter activity?
Key genes include SLC7A5 (LAT1), SLC16A10 (MCT10), SLC43A2 (LAT4), and SLC3A2 (4F2hc), among others.
Which diseases are linked to aromatic amino acid transporters?
They are linked to cancer, neurological disorders, and metabolic diseases such as Hartnup disorder.
How can I study aromatic amino acid transport in the lab?
Common methods include radiolabeled uptake assays, CRISPR knockout, structural biology, and proteomics.
What is the role of LAT1 (SLC7A5) in cancer?
LAT1 is often overexpressed in cancer to supply aromatic amino acids for growth and is a target for therapy.
Can CRISPR be used to create models for aromatic amino acid transporters?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are widely used to study these transporters.
What is the substrate specificity of MCT10 (SLC16A10)?
MCT10 transports aromatic amino acids and thyroid hormones, and its specificity can be altered by few amino acid exchanges.
How is aromatic amino acid transport regulated?
It is regulated transcriptionally by oncogenes like MYC, and post-translationally by interactions with accessory proteins like 4F2hc.
What are the symptoms of Hartnup disorder?
Hartnup disorder, caused by mutations in SLC6A19, leads to impaired neutral amino acid transport and can cause neurological symptoms.
Does EDITGENE provide services for aromatic amino acid transporter research?
Yes, EDITGENE offers CRISPR knockout, point mutation, knock-in, overexpression, library screening, and bioinformatics services for these targets.
Conclusion
Aromatic amino acid transmembrane transporter activity (GO:0015173) is a fundamental molecular function that governs the cellular uptake of essential aromatic amino acids. Its dysregulation is implicated in cancer, neurological disorders, and metabolic diseases, making it a compelling target for research and therapeutic development. Advances in structural biology and CRISPR-based models continue to unravel the complexities of these transporters. EDITGENE's comprehensive CRISPR services empower researchers to create precise models to study aromatic amino acid transporters, from knockout to knock-in and overexpression, facilitating discoveries that can translate into clinical applications.
References
- 1. Halestrap AP. 2013. The SLC16 gene family - structure, role and regulation in health and disease.. Mol Aspects Med 34(2-3):337-49 PMID: 23506875
- 4. Johannes J et al.. 2016. Few Amino Acid Exchanges Expand the Substrate Spectrum of Monocarboxylate Transporter 10.. Mol Endocrinol 30(7):796-808 PMID: 27244477
- 5. Chen S et al.. 2024. Structure-activity characteristics of phenylalanine analogs selectively transported by L-type amino acid transporter 1 (LAT1).. Sci Rep 14(1):4651 PMID: 38409393
- 6. Lee Y et al.. 2025. Structural basis of anticancer drug recognition and amino acid transport by LAT1.. Nat Commun 16(1):1635 PMID: 39952931
- 8. Becker PC et al.. 2024. Identification of Human TRIAC Transmembrane Transporters.. Thyroid 34(7):920-930 PMID: 38801167
